Interestingly, brigatinib also showed obvious anti-neoplastic activity in several ALK-negative cancer cell lines (Figure S1B), suggesting the presence of an ALK-independent anti-cancer mechanism for brigatinib. This evidence concerns the gene ALK and cancer.